Tissue factor expression in salivary gland carcinoma: A potential novel therapeutic target for advanced disease Journal Article

   

Authors:	Jansen, L.; Nachtsheim, L.; Wolber, P.; Shabli, S.; Esser, J.; Quaas, A.; Morris, L. G. T.; Ho, A. L.; Klussmann, J. P.; Arolt, C.; Mayer, M.
Article Title:	Tissue factor expression in salivary gland carcinoma: A potential novel therapeutic target for advanced disease
Abstract:	Background: Salivary gland carcinomas (SGC) are rare head and neck malignancies with diverse molecular profiles and treatment challenges. Tissue factor (TF), a transmembrane glycoprotein involved in cancer pathophysiology, has emerged as a potential therapeutic target.Objectives: The objective of this study was to investigate TF expression in SGC and its correlation with clinicopathological data.Design: A cohort of 109 SGC patients who underwent curative surgery between 1990 and 2023 was analyzed.Methods: TF expression in primaries and lymph node (LN) metastases was assessed using immunohistochemistry on tissue microarrays. Histo-scores were calculated for cytoplasmic and membranous staining and correlated with clinicopathological data.Results: TF was expressed in 80.7% of samples with a mean combined H-score of 29.6. Moderate and high expression was found in 22.9% of all cases. Mucoepidermoid carcinoma (MEC), secretory carcinoma, and salivary duct carcinoma (SDC) showed the highest expression. A significantly higher membranous TF expression was observed in SDC LN metastases compared to primaries (71.1 vs 31.7, p = 0.012). Survival analysis revealed a trend toward worse outcomes for tumors with higher TF expression.Conclusion: This study provides the first analysis of TF expression in SGC revealing its presence across various subtypes. The findings suggest potential for TF-targeted therapies in SGC treatment, particularly for metastatic SDC and MEC. The trend toward worse survival outcomes in high TF-expressing tumors warrants further investigation.
Keywords:	targeted therapy; salivary gland cancer; tumor; salivary duct carcinoma; tissue factor; antibody-drug conjugate; head and neck oncology
Journal Title:	Therapeutic Advances in Medical Oncology
Volume:	17
ISSN:	1758-8340
Publisher:	Sage Publications Ltd.
Date Published:	2025-01-01
Start Page:	17588359251357727
Language:	English
ACCESSION:	WOS:001556242800001
DOI:	10.1177/17588359251357727
PROVIDER:	wos
PMCID:	PMC12374091
PUBMED:	40861316
Notes:	Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/228429